Xcout IntelPharos iBio
Pharos iBio Co., Ltd. is a South Korean biotechnology company that uses artificial intelligence and big-data approaches for drug discovery and development. Its pipeline includes oncology candidates such as PHI-101, a FLT3 inhibitor being developed for acute myeloid leukemia and other cancers, serving patients with difficult-to-treat diseases and pharmaceutical development partners.
Subscribe to see Pharos iBio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Pharos iBio at a glance
Pharos iBio is a biotechnology company headquartered in South Korea. It has raised at least $15.9M across the 2 funding rounds on record, 1 of them with a disclosed amount. Its most recent funding round, Debt, closed in December 2025.
Pharos iBio funding rounds
At least $15.9M raised across the 2 rounds on record (1 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Debt | Undisclosed | — | |
| — | $15.9M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Pharos iBio competitors
A few of Pharos iBio's closest competitors — see the full list of competitors and alternatives →
9Bio Therapeutics is a biotechnology company that combines biology, structural engineering, and artificial intelligence to pioneer next-generation biologics for advanced cancers. The company is headquartered in Quebec, Canada.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Metaphore Biotechnologies, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, operating as part of Flagship Pioneering. The company focuses on therapeutic design, leveraging AI and machine learning technologies for drug discovery and development.
Great Bay Bio is a biotech company headquartered in HKSTP that drives drug development using cutting-edge technologies such as AI and big data mining.
Sightera Biosciences is an Antwerp-based biotechnology startup leveraging clinically correlated patient data and an artificial intelligence platform to advance drug discovery and design.
Cellarity is a U.S. biotechnology company that uses single-cell biology, computational modeling, and machine learning to discover medicines based on cellular behaviors and disease mechanisms. It serves pharmaceutical and biotechnology development needs, advancing its own therapeutic programs and potentially partnering with other drug developers.
Get Pharos iBio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Pharos iBio in Xcout Intel
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access